The Cost-Effectiveness of Maturity-Onset Diabe... [Diabetes Care. 2013] - PubMed - NCBI

Public Health Sciences

The cost-effectiveness of maturity-onset diabetes of the young genetic testing - translating genomic advances into practical health applications
Naylor RN, et al. Diabetes Care 2013 Sep
The establishment of core competencies for Canadian genetic counsellors: Validation of practice based competencies
Ferrier RA, et al. J Genet Couns 2013 Sep
Genetic susceptible locus in NOTCH2 interacts with arsenic in drinking water on risk of Type 2 Diabetes.
Pan WC, et al. PLoS One. 2013 Aug 14;8(8):e70792
Genome-wide association analysis of blood-pressure traits in African-ancestry individuals reveals common associated genes in African and non-African populations.
Franceschini N, et al. Am J Hum Genet. 2013 Sep 5;93(3):545-54.

Genes tied to high blood pressure found in black Americans, U.S. News & World Report, Sep 16

Genotype- and phenotype-directed personalization of antiplatelet treatment in patients with non-ST elevation acute coronary syndromes undergoing coronary stenting
Ahn SG, et al. Korean Circ J 2013 Aug;43(8):541-9
A host-based RT-PCR gene expression signature to identify acute respiratory viral infection
Zaas A, et al. Sci Transl Med 5(203):203ra126 2013 Sep 18

Study supports potential of PCR-based blood test for respiratory virus infection, Genome Web, Sep 18 [by free subscription only]

Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of research
Ioannou L, et al. Genet Med 2013 Sep
Reproducibility of high-throughput mRNA and small RNA sequencing across laboratories.
Peter A C 't Hoen et al. Nature Biotechnology, September 15
The return of unexpected research results in a biobank study and referral to health care for heritable Long QT syndrome
Haukkala A, et al. Public Health Genomics 2013 Sep:241-50
Stakeholder engagement: a key component of integrating genomic information into electronic health records
Hartzler A, et al. Genet Med 2013 Sep

The Cost-Effectiveness of Maturity-Onset Diabe... [Diabetes Care. 2013] - PubMed - NCBI

Diabetes Care. 2013 Sep 11. [Epub ahead of print]

The Cost-Effectiveness of Maturity-Onset Diabetes of the Young Genetic Testing - Translating Genomic Advances into Practical Health Applications.

Naylor RN, John PM, Winn AN, Carmody D, Greeley SA, Philipson LH, Bell GI, Huang ES.

Source

Department of Pediatrics, Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, University of Chicago, Chicago, Illinois;

Abstract

ObjectiveTo evaluate the cost-effectiveness of a genetic testing policy for HNF1A, HNF4A and GCK-MODY in a hypothetical cohort of type 2 diabetes patients 25-40 years old with a MODY prevalence of 2%.Research Design and MethodsWe used a simulation model of type 2 diabetes complications based on UKPDS data, modified to account for the natural history of disease by genetic subtype, to compare a policy of genetic testing at diabetes diagnosis versus a policy of no testing. Under the screening policy, successful sulfonylurea treatment of HNF1A-MODY and HNF4A-MODY was modeled to produce a glycosylated hemoglobin reduction of -1.5%, compared to usual care. GCK-MODY received no therapy. Main outcome measures were costs and quality-adjusted life years (QALYs), based on lifetime risk of complications and treatments, expressed as the incremental cost-effectiveness ratio (ICER, $/QALY).ResultsThe testing policy yielded an average gain of 0.012 QALYs and resulted in an ICER of $205,000. Sensitivity analysis showed that if the MODY prevalence was 6%, the ICER would be ∼$50,000. If MODY prevalence was >30%, the testing policy was cost-saving. Reducing genetic testing costs to $700 also resulted in an ICER of ∼$50,000.ConclusionsOur simulated model suggests a policy of testing for MODY in selected populations is cost-effective for the United States based on contemporary ICER thresholds. Higher prevalence of MODY in the tested population or decreased testing costs would enhance cost-effectiveness. Our results make a compelling argument for routine coverage of genetic testing in patients with high clinical suspicion of MODY.

PMID:

24026547

[PubMed - as supplied by publisher]